Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRPHRODITE open-label extension of lunsekimig in adult asthma
2025-522896-27-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- May 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 2, open-label, single-arm trial of lunsekimig in asthma, sponsored by Sanofi. Primary endpoint: Exposure-adjusted incidence rate of treatment-emergent adverse events including AESIs and SAEs. Planned start May 2026; status: authorised.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on 2025-522896-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522896-27-00.